SCOTT VAFAI
Osteopathic Medicine at Francis St, Boston, MA
License number
Massachusetts 232408
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
75 Francis St, Boston, MA 02115
Phone
(617) 525-6841
Personal information
See more information about SCOTT VAFAI at radaris.comName
Address
Phone
109 Queensberry St, Boston, MA 02215
109 Queensberry St, Boston, MA 02215
Organization information
See more information about SCOTT VAFAI at bizstanding.comScott Vafai MD
75 Francis St, Boston, MA 02115
Industry:
Internist
Phone:
(617) 525-6841 (Phone)
Scott B. Vafai
Professional information
See more information about SCOTT VAFAI at trustoria.com
Dr. Scott Vafai, Boston MA - MD (Doctor of Medicine)
Dr. Scott Vafai, Boston MA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism
Age:
43
Address:
75 Francis St, Boston 02115
(617) 525-6841 (Phone)
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone)
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone)
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone)
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone)
75 Francis St, Boston 02115
(617) 525-6841 (Phone)
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone)
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone)
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone)
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone)
75 Francis St, Boston 02115
Certifications:
Diabetes, Metabolism & Endocrinology, 2012, Internal Medicine, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
75 Francis St, Boston 02115
75 Francis St, Boston 02115
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
Brigham and Women's Hospital
75 Francis St, Boston 02115
75 Francis St, Boston 02115
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
BRIGHAM AND WOMENS HOSPITAL
75 Francis St, Boston 02115
Brigham and Women's Hospital
75 Francis St, Boston 02115
Education:
Medical School
Harvard Med Sch
Graduated: 2006
Harvard Med Sch
Graduated: 2006
Modulation Of Protein Methylation And Phosphoprotein Phosphate
Modulation Of Protein Methylation And Phosphoprotein Phosphate
US Patent:
2007003, Feb 8, 2007
Filed:
Mar 13, 2003
Appl. No.:
10/579369
Inventors:
Gregory Stock - Los Angeles CA, US
Jeffry Stock - Rocky Hill NJ, US
Maxwell Stock - Rocky Hill NJ, US
Scott Vafai - Boston MA, US
Jeffry Stock - Rocky Hill NJ, US
Maxwell Stock - Rocky Hill NJ, US
Scott Vafai - Boston MA, US
International Classification:
A61K 36/00, C12Q 1/42
US Classification:
435021000, 424725000
Abstract:
The invention relates to methylated proteins that control protein phosphorylation, particularly phosphoesterases, such as PP2A. It relates to screening methods for determining agents that affect methylation of these proteins and thus also modulate the level of phosphorylation of phosphoproteins. It relates as well to the agents and to compositions comprising the agents. In a particular aspect in this regard the invention relates to agents that alter PP2A methylation and that thereby affect phosphorylation of phosphoproteins that play an important role in health or disease, such as the tau protein which is implicated in the etiology of Alzheimer's Disease. The invention further relates to diagnostic methods based on protein methylation levels, to compositions comprising agents for affecting methylation of proteins and for controlling the phosphate complement of phosphoproteins. Additionally, the invention relates to methods for administering the agents and compositions to affect methylation of proteins physiologically and to modulate the phosphate complement of phosphoproteins. Examples in this regard include agents and compositions that affect physiological activity of PP2A and alter the phosphate complement of phosphoproteins that are altered in disease.
Hepatic Denervation Systems
Hepatic Denervation Systems
US Patent:
2014006, Mar 6, 2014
Filed:
Nov 8, 2013
Appl. No.:
14/075949
Inventors:
Bobak Robert Azamian - Newport Coast CA, US
Scott Bradley Vafai - Boston MA, US
Scott Bradley Vafai - Boston MA, US
Assignee:
METAVENTION, INC. - Newport Beach CA
International Classification:
A61B 18/18
US Classification:
606 33
Abstract:
According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.
Gastroduodenal Artery Neuromodulation
Gastroduodenal Artery Neuromodulation
US Patent:
2014006, Mar 6, 2014
Filed:
Nov 8, 2013
Appl. No.:
14/075976
Inventors:
Jonathan Allen Coe - Menlo Park CA, US
Scott Bradley Vafai - Boston MA, US
Scott Bradley Vafai - Boston MA, US
Assignee:
METAVENTION, INC. - Newport Beach CA
International Classification:
A61B 18/18, A61N 7/00, A61B 17/32, A61N 5/00
US Classification:
606 33, 607101, 606169
Abstract:
According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.
Devices For Thermally-Induced Hepatic Neuromodulation
Devices For Thermally-Induced Hepatic Neuromodulation
US Patent:
8579891, Nov 12, 2013
Filed:
Mar 7, 2013
Appl. No.:
13/789509
Inventors:
Bobak Robert Azamian - Newport Coast CA, US
Scott Bradley Vafai - Boston MA, US
Scott Bradley Vafai - Boston MA, US
Assignee:
Metavention, Inc. - Newport Beach CA
International Classification:
A61B 18/18
US Classification:
606 33, 606 41, 606 45
Abstract:
According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e. g. , hepatic artery) having surrounding nerves that innervate the liver (e. g. , sympathetic nerves of the hepatic plexus). The method may also include modulating (e. g. , disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.
Treatment Of Non-Alcoholic Fatty Liver Disease
Treatment Of Non-Alcoholic Fatty Liver Disease
US Patent:
2014006, Mar 6, 2014
Filed:
Nov 8, 2013
Appl. No.:
14/075908
Inventors:
Jonathan Allen Coe - Menlo Park CA, US
Scott Bradley Vafai - Boston MA, US
Scott Bradley Vafai - Boston MA, US
Assignee:
METAVENTION, INC. - Newport Beach CA
International Classification:
A61B 18/14, A61B 18/18
US Classification:
606 33
Abstract:
According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.
Neuromodulation Methods Using Balloon Catheter
Neuromodulation Methods Using Balloon Catheter
US Patent:
2014006, Mar 6, 2014
Filed:
Nov 8, 2013
Appl. No.:
14/076011
Inventors:
Jonathan Allen Coe - Menlo Park CA, US
Scott Bradley Vafai - Boston MA, US
Scott Bradley Vafai - Boston MA, US
Assignee:
METAVENTION, INC. - Newport Beach CA
International Classification:
A61B 18/14, A61B 18/18
US Classification:
606 33
Abstract:
According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.
Methods For Thermally-Induced Hepatic Neuromodulation
Methods For Thermally-Induced Hepatic Neuromodulation
US Patent:
8568399, Oct 29, 2013
Filed:
Mar 7, 2013
Appl. No.:
13/789521
Inventors:
Scott Bradley Vafai - Boston MA, US
Jonathan Allen Coe - Menlo Park CA, US
Jonathan Allen Coe - Menlo Park CA, US
Assignee:
Metavention, Inc. - Newport Beach CA
International Classification:
A61B 18/18
US Classification:
606 33, 606 41
Abstract:
According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e. g. , hepatic artery) having surrounding nerves that innervate the liver (e. g. , sympathetic nerves of the hepatic plexus). The method may also include modulating (e. g. , disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.
Hepatic Neuromodulation Devices
Hepatic Neuromodulation Devices
US Patent:
2014006, Mar 6, 2014
Filed:
Nov 1, 2013
Appl. No.:
14/069744
Inventors:
Bobak Robert Azamian - Newport Coast CA, US
Scott Bradley Vafai - Boston MA, US
Scott Bradley Vafai - Boston MA, US
Assignee:
METAVENTION, INC. - Newport Beach CA
International Classification:
A61B 18/18, A61N 5/00
US Classification:
606 33, 607101
Abstract:
According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.